Mintz Levin Represents Cyclacel Pharmaceuticals Inc. in Sale of Patents to
Celgene Corporation For $5.5 Million and Dismissal of All Claims Against
Celgene in Patent Litigation
NEW YORK -- April 5, 2013
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cyclacel
Pharmaceuticals Inc. in a patent infringement action in which Cyclacel accused
Celgene Corporation of infringing four patents related to the use of
romidepsin to treat disease. (D.Del. 1:10‐cv‐00348‐GMS).
The two companies have filed a joint stipulation and the Court has entered an
order dismissing the pending litigation. The parties entered into a definitive
agreement with Cyclacel selling the four Cyclacel‐owned patents to Celgene. In
connection with the agreement Celgene has made to Cyclacel a one‐time payment
of $5.5 million.
Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
Representing Cyclacel in the patent litigation agreement were John Bauer, Ivor
Elrifi, Marv Gittes and Timur Slomin, Members in the Intellectual Property
Practice. Avisheh Avini, an associate in the firm’s Corporate & Securities
Practice, also assisted in the agreement.
For more information about Mintz Levin, please visit www.mintz.com.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Gina Addis, 617-348-4413
Press spacebar to pause and continue. Press esc to stop.